Program
AP 1903 reagent
Also written as “Rimiducid (AP1903)”, “BPX-501 and Rimiducid” and “Rimiducid”.
Its studies are mostly in Thymoma · Primary Immunodeficiency Diseases · Precursor Cell Lymphoblastic Leukemia-Lymphoma · Hematologic Neoplasms · Prostatic Neoplasms, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bellicum Pharmaceuticals | 52 open or running | phase 2since Sep 29, 2017 | Mar 24, 2009 | none ahead |
| Beijing Biotech | 11 open or running | phase 2since May 14, 2026 | May 14, 2026 | Jun 14, 2027phase 2 · NCT07598955 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 24, 2009First study: phase 1 study in Castrate Resistant Prostate Cancer (CRPC)New to Bellicum PharmaceuticalsBellicum Pharmaceuticals · NCT00868595 · 18 enrolled · United States
- Mar 21, 2013Phase 1 study in Neoplasm MetastasisBellicum Pharmaceuticals · NCT01823978 · 19 enrolled · United States
- Aug 28, 2014Phase 1 study in Primary Immunodeficiency DiseasesBellicum Pharmaceuticals · NCT02231710 · 1 enrolled · United States
- Sep 29, 2017Phase 2 study in Precursor Cell Lymphoblastic Leukemia-LymphomaBellicum Pharmaceuticals · NCT03301168 · 120 enrolled · United States
- Feb 23, 2018Phase 1 study in Hematologic NeoplasmsBellicum Pharmaceuticals · NCT03459170 · 15 enrolled · Italy
- May 14, 2026Beijing Biotech's first study: phase 2 study in ThymomaNew to Beijing BiotechBeijing Biotech · NCT07598955 · 36 planned · China
Ahead
- Jun 14, 2027Primary completion: phase 2 study in ThymomaBeijing Biotech · NCT07598955
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07598955Thymoma · China | 2 | Recruiting | Beijing Biotech | Jun 14, 2027 | 36 |
| NCT03459170Hematologic Neoplasms · Italy | 1 | Active, not recruiting | Bellicum Pharmaceuticals | Sep 2022 | 15 |
| NCT03301168Precursor Cell Lymphoblastic Leukemia-Lymphoma · United States | 2 | Active, not recruiting | Bellicum Pharmaceuticals | May 11, 2021 | 120 |
| NCT02231710Primary Immunodeficiency Diseases · United States | 1 | Terminated | Bellicum Pharmaceuticals | Sep 2015 | 1 |
| NCT01823978Neoplasm Metastasis · United States | 1 | Completed | Bellicum Pharmaceuticals | May 2016 | 19 |
| NCT00868595Castrate Resistant Prostate Cancer (CRPC) · United States | 1 | Completed | Bellicum Pharmaceuticals | Jul 2011 | 18 |
How it is read
Names in the registry
- “Rimiducid (AP1903)”, 1 entry
- “BPX-501 and Rimiducid”, 1 entry
- “Rimiducid”, 1 entry
- “rimiducid”, 1 entry
- “AP1903”, 1 entry
Conditions, from the studies’ own filings
- Thymoma, 1 study
- Primary Immunodeficiency Diseases, 1 study
- Precursor Cell Lymphoblastic Leukemia-Lymphoma, 1 study
- Hematologic Neoplasms, 1 study
- Prostatic Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.